J Korean Med Sci.  2011 Jun;26(6):807-813. 10.3346/jkms.2011.26.6.807.

Prostate Volume has Prognostic Value Only in Pathologic T2 Radical Prostatectomy Specimens

• Cho IC
• Kwon WA
• Kim JE
• Joung JY
• Seo HK
• Chung J
• Park WS
• Lee KH

• KMID: 1785969
• DOI: http://doi.org/10.3346/jkms.2011.26.6.807

Abstract

The objective of this study was to evaluate the prognostic roles of the prostate volume, tumor volume, and tumor percentage as a function of the pathologic T stage in radical prostatectomy specimens. This study included 259 patients who underwent radical prostatectomy between 2005 and 2010. The mean follow-up period was 41.2 months. In all of the specimens, prostate volume (P = 0.021), the Gleason score (P = 0.035), and seminal vesicle invasion (P = 0.012) were independent predictors of biochemical recurrence (BCR). In the T2 group, multivariate analysis showed that the BCR was significantly associated with prostate specific antigen (PSA) (P = 0.028), a lower prostate volume (P = 0.004), and the Gleason score (P = 0.040). The Kaplan-Meier survival curve showed that a smaller prostate volume was significantly associated with a greater risk of BCR (< 30 vs > or = 30 mL; P = 0.010). In the T3 group, patients with seminal vesicle invasion had a significantly shorter mean BCR-free survival (P = 0.030). In this study, tumor volume and tumor percentage did not predict BCR. Notably, a lower prostate volume is an independent predictor for BCR only in the organ-confined radical prostatectomy specimens. But, prostate volume could not predict BCR in most locally advanced tumors.

Keyword

Prostate; Prostatic Neoplasms; Prostatectomy; Volume

MeSH Terms

Aged
Aged, 80 and over
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Recurrence, Local/diagnosis
Neoplasm Staging
Organ Size
Predictive Value of Tests
Prostate/*pathology
Prostate-Specific Antigen/blood
Prostatectomy
Prostatic Neoplasms/*pathology/surgery
Retrospective Studies
Risk Factors

Figure

• 

  Fig. 1 BCR-free survival curves according to the prostate volume in all (A) and pT2 (B) specimens.

Reference

1. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci. 2009. 24:995–1003.

2. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010. 25:1113–1121.

3. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998. 90:766–771.

4. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology. 1993. 41:113–120.

5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999. 281:1591–1597.

6. Stein A, deKernion JB, Dorey F. Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. Br J Urol. 1991. 67:626–631.

7. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol. 2005. 23:4975–4979.

8. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996. 20:286–292.

9. Ates M, Teber D, Gozen AS, Tefekli A, Sugiono M, Hruza M, Rassweiler J. Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis. J Urol. 2007. 177:1771–1775.

10. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Loughlin KR, Richie JP, Wein A. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol. 1998. 16:3094–3100.

11. Guzzo TJ, Vira MA, Dey W, Hwang WT, Tomaszewski J, VanArsdalen K, Wein AJ, Malkowicz B. Re: Guzzo TJ, Vira MA, Neway W, et al: Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology 69: 1147-1151, 2007. Urology. 2008. 71:1230–1231.

12. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC Jr, Kane CJ. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005. 23:7546–7554.

13. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 1993. 149:1478–1481.

14. Merrill MM, Lane BR, Reuther AM, Zhou M, Magi-Galluzzi C, Klein EA. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology. 2007. 70:294–298.

15. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974. 111:58–64.

16. Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol. 1997. 107:704–708.

17. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999. 17:1499–1507.

18. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010. 105:472–475.

19. Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol. 2008. 180:571–576.

20. Hong SK, Yu JH, Han BK, Chang IH, Jeong SJ, Byun SS, Lee HJ, Choe G, Lee SE. Association of prostate size and tumor grade in Korean men with clinically localized prostate cancer. Urology. 2007. 70:91–95.

21. Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008. 11:371–376.

22. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003. 169:1670–1675.

23. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology. 1998. 52:631–636.

24. Yadav R, Tu JJ, Jhaveri J, Leung RA, Rao S, Tewari AK. Prostate volume and the incidence of extraprostatic extension: is there a relation? J Endourol. 2009. 23:383–386.

25. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, Kattan MW. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006. 98:715–717.

26. Carvalhal GF, Humphrey PA, Thorson P, Yan Y, Ramos CG, Catalona WJ. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer. 2000. 89:1308–1314.

27. Manoharan M, Civantos F, Kim SS, Gomez P, Soloway MS. Visual estimate of percent of carcinoma predicts recurrence after radical prostatectomy. J Urol. 2003. 170:1194–1198.

28. Nelson BA, Shappell SB, Chang SS, Wells N, Farnham SB, Smith JA Jr, Cookson MS. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006. 97:1169–1172.

29. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999. 281:1395–1400.